Modified Factor VIII Polypeptides for Lower-Dose Hemophilia A Gene Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for hemophilia A, such as recombinant factor VIII infusion and gene therapy, are costly, require intravenous delivery, and face challenges with bioavailability and vector toxicity, limiting their widespread implementation.

Innovation Solution

Development of modified plasma clotting factor VIII polypeptides (mhFVIII) with specific amino acid substitutions to enhance coagulation activity, secretion, and specific activity, potentially reducing the dose of viral vectors needed for gene therapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If gene therapy is used to treat hemophilia A, then factor VIII production is improved, but vector toxicity increases

Engineering Contradiction:

Improvefactor VIII productionVSAvoidvector toxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the factor VIII protein sequence by introducing specific amino acid substitutions (e.g., at positions 21, 57, 69, 80, 178, 199, 212, 215, 269, 310, 318, 332, 378, 610, 661) to change its properties. These parameter changes in the protein structure aim to enhance secretion efficiency and coagulation activity while reducing the viral vector dose required, thereby mitigating vector toxicity.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If high viral vector doses are used for gene therapy, then factor VIII expression levels are improved, but treatment expenses increase

Engineering Contradiction:

Improvefactor VIII expression levelsVSAvoidtreatment expenses

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

By modifying the factor VIII protein sequence with specific amino acid substitutions, the patent aims to enhance the protein's secretion efficiency and coagulation activity. This should allow achieving therapeutic expression levels with lower viral vector doses, thereby reducing treatment expenses while maintaining effective factor VIII expression.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates modified versions of the native factor VIII protein through amino acid substitutions. These modified copies (mhFVIII) are designed to have improved properties compared to the wild-type protein, potentially achieving better therapeutic outcomes with reduced vector requirements.

Inventive Principle:

Principle #26Copying

3Reliability

If recombinant factor VIII infusion is used, then clotting function is improved, but treatment cost and complexity increase

Engineering Contradiction:

Improveclotting functionVSAvoidtreatment cost and complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces specific amino acid substitutions in the factor VIII sequence to modify its properties, aiming to enhance secretion efficiency and coagulation activity. This could lead to more effective treatment with potentially lower doses and reduced complexity compared to current recombinant factor VIII infusions.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12583907B2Modified plasma clotting factor VIII and method of use thereof

Publication Date: 2026.03.24 AAVNERGENE INC

AI summary

Modified human factor VIII polypeptides with enhanced factor VIII activity are described. In some embodiments, the modified human factor VIII polypeptides comprise one or more amino acid substitutions at positions A20, T21, F57, L69, I80, L178, R199, H212, I215, R269, I310, L318, S332, R378, I610 and/or I661. Such polypeptides and viral vectors encoding such polypeptides may be used for treatment of FVIII deficiencies, such as hemophilia A.